Baylor College of Medicine

CurePSP Recognizes Three Prominent Medical Institutions for Their Care for PSP, CBD and MSA

Retrieved on: 
Thursday, October 5, 2023

PSP, CBD and MSA, which are considered "atypical parkinsonian syndromes," often go underrecognized and underdiagnosed.

Key Points: 
  • PSP, CBD and MSA, which are considered "atypical parkinsonian syndromes," often go underrecognized and underdiagnosed.
  • Additionally, autonomic dysfunction (e.g., blood pressure regulation, urinary control) is a hallmark feature of MSA, while PSP and CBD can present with cognitive impairment and difficulty expressing words.
  • "The continued growth of our care network is one impactful way we can work toward improving the standard of care for PSP, CBD and MSA."
  • "Through becoming a CurePSP Center of Care, our ability to care for our patients will only expand and strengthen," Dr. Brown said.

Veru Reports Muscle Data from 5 Clinical Studies of Enobosarm that Support the Advancement of Enobosarm in Combination with Weight-Loss GLP-1 Drugs, Ozempic®, Wegovy®, or Mounjaro®, to Optimize Weight Loss by Preventing Muscle Wasting and Further Increasi

Retrieved on: 
Wednesday, October 4, 2023

MIAMI, FL, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on developing novel medicines for the treatment of obesity, breast cancer and for viral induced ARDS, today announced that the Company will advance its proprietary novel agent, enobosarm, a selective androgen receptor modulator (SARM), into a Phase 2b clinical trial in combination with weight-loss GLP-1 drugs, Ozempic (semaglutide), Wegovy (semaglutide), or Mounjaro (tirzepatide) to evaluate the efficacy and the safety of enobosarm to further increase fat loss while preventing the significant muscle wasting that occurs with weight-loss GLP-1 drugs.

Key Points: 
  • Specifically, enobosarm therapy could augment the preferential loss of fat mass while preventing the loss of critical muscle mass and bone mineral density.
  • Enobosarm treatment could also preserve or improve muscle strength and physical function in older adults being treated with a weight loss drug.
  • The primary endpoint of the study will be change in total lean body mass (muscle) from baseline to 4 months.
  • Key secondary endpoints will be change from baseline to 4 months in total fat mass, insulin resistance (HOMA-IR), and body weight.

Heart Failure (HF) Rate Expected to Rise to 8.5 Million Americans by 2030. New HFSA Initiative Identifies Rapidly Changing Landscape of HF in the U.S.

Retrieved on: 
Tuesday, October 3, 2023

ROCKVILLE, Md., October 3, 2023 /PRNewswire/ -- HF StatsSM, a new initiative by the Heart Failure Society of America (HFSA) , revealed that one in four individuals are projected to develop heart failure (HF) in their lifetime.

Key Points: 
  • ROCKVILLE, Md., October 3, 2023 /PRNewswire/ -- HF StatsSM, a new initiative by the Heart Failure Society of America (HFSA) , revealed that one in four individuals are projected to develop heart failure (HF) in their lifetime.
  • HF StatsSM presents the latest data on the epidemiology, differences, and outcomes according to sex, race, ethnicity, and age.
  • The HF StatsSM Initiative seeks to fill this gap by providing essential heart failure data to clinicians, researchers, policymakers, and patients living with HF.
  • Approximately 6.7 million Americans over 20 years of age have heart failure (HF), and the prevalence is expected to rise to 8.5 million Americans by 2030.

Incorporating the Patient's Voice in NASH Clinical Trials, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Tuesday, October 3, 2023

TORONTO, Oct. 3, 2023 /PRNewswire-PRWeb/ -- There is immense interest in finding new therapies for non-alcoholic steatohepatitis (NASH), which is increasingly being known as metabolic-associated steatohepatitis (MASH), due to the unmet need and race to the market to get the first treatment approved. In parallel, the rates of MASH are increasing, and it is linked to the global obesity epidemic and related metabolic disorders. MASH is now expected to be the leading indication for liver transplant in the next few years, surpassing hepatitis C and Alcoholic Hepatitis. Despite the high rates of MASH, recruitment to clinical trials remains challenging in NASH clinical trials.

Key Points: 
  • Attendees will learn how to partner across the industry to improve the patient experience by using patient-centric trial strategies in NASH clinical trials.
  • The featured speakers will discuss the strategies to include the patient voice to aid in NASH patient recruitment and retention for clinical trials.
  • Despite the high rates of MASH, recruitment to clinical trials remains challenging in NASH clinical trials.
  • The panel will also discuss the way forward for building on the voice of patients to define strategies to improve patient recruitment and retention in NASH clinical trials.

Neural Therapeutics Announces Board of Directors Appointments and IP Development Agreement with Validity Labs

Retrieved on: 
Tuesday, October 3, 2023

The Company is also pleased to announce that it has entered into IP development agreement ("Agreement") with Validity Laboratory Services LLC ("Validity Labs").

Key Points: 
  • The Company is also pleased to announce that it has entered into IP development agreement ("Agreement") with Validity Laboratory Services LLC ("Validity Labs").
  • Following these appointments, the board of directors of Neural is comprised of Ian Campbell, John Durfy, Colin McLelland, Dr. Kelly Narine and Dr. Jason Dyck.
  • Ian Campbell, CEO of Neural commented: "The expansion of our partnership with CGS and Validity Labs allows us to foster collaborative relationships with Validity Labs and leverage their extensive capabilities and expertise.
  • In connection with the Agreement entered between Neural and Validity Labs, Neural issued 500,000 common shares in the capital of Neural ("Neural Shares"), which was included in debt settlement issuance as outlined in Neural press release dated October 2, 2023.

TWO BEAR CAPITAL OPENS NEW YORK HEADQUARTERS IN THE ALEXANDRIA CENTER FOR LIFE SCIENCE

Retrieved on: 
Monday, October 2, 2023

NEW YORK, Oct. 2, 2023 /PRNewswire/ -- Two Bear Capital, the venture capital firm investing in disruptors in biotechnology, bioinformatics, healthcare IT, machine learning and AI, and information security, today announced the opening of its New York headquarters within the Alexandria Center for Life Science in New York City. With a mission to create and grow the life sciences ecosystems and clusters that ignite and accelerate the world's leading innovators, the Alexandria Center is the ideal location from which Two Bear Capital will operate in New York.

Key Points: 
  • With a mission to create and grow the life sciences ecosystems and clusters that ignite and accelerate the world's leading innovators, the Alexandria Center is the ideal location from which Two Bear Capital will operate in New York.
  • Two Bear Capital is focused on harnessing life sciences and technology to solve the world's toughest challenges.
  • Mike Goguen, Founder and Managing Partner of Two Bear Capital said; "Opening the Two Bear Capital offices in New York represents a real milestone for our firm.
  • Two Bear Capital's New York headquarters are located at 430 East 29th Street, Suite 945, New York, NY 10016.

From AI to Slide-Free Imaging: The 2023 Next-Gen Digital Pathology Conference Sheds Light on Medicine's Future (Boston, United States - October 19-20th, 2023)

Retrieved on: 
Friday, September 29, 2023

Other highlights include innovative research displays, sessions on AI's role in drug discovery, and workshops centered on ensuring quality in digital pathology.

Key Points: 
  • Other highlights include innovative research displays, sessions on AI's role in drug discovery, and workshops centered on ensuring quality in digital pathology.
  • Day 1 (19th Oct) focuses on the strategic aspects, challenges, and scopes of digital pathology with keynotes on the future developments and implications of the technology.
  • Day 2 (20th Oct) delves into computational pathology, AI's influence on imaging and digital image analysis, and an in-depth look at how digital pathology and AI are revolutionizing pathology labs.
  • Sunil Singhal, Chief of Digital Pathology Transformation, Baylor College of Medicine
    Shoh Asano, Principal Scientist Microscopy and Image Analysis, Pfizer

TEXAS CHILDREN'S HOSPITAL CENTER FOR VACCINE DEVELOPMENT TEAM RECEIVES 2023 DAVID AND BEATRIX HAMBURG AWARD FOR VACCINE TECHNOLOGY DEVELOPMENT

Retrieved on: 
Thursday, September 28, 2023

HOUSTON, Sept. 28, 2023 /PRNewswire/ -- Texas Children's Hospital is pleased to announce that the Texas Children's Hospital Center for Vaccine Development team has been awarded the 2023 David and Beatrix Hamburg Award for their development of a recombinant protein-based COVID-19 vaccine technology, created in Houston, which has benefited millions of people around the world.

Key Points: 
  • HOUSTON, Sept. 28, 2023 /PRNewswire/ -- Texas Children's Hospital is pleased to announce that the Texas Children's Hospital Center for Vaccine Development team has been awarded the 2023 David and Beatrix Hamburg Award for their development of a recombinant protein-based COVID-19 vaccine technology, created in Houston, which has benefited millions of people around the world.
  • "This recognition reinforces the importance of fostering exceptional, creative and interdisciplinary scientific teams to advance biomedical sciences that benefit humanity."
  • In India, the vaccine is produced under the name Corbevax by Biological E. Limited.
  • Botswana has also approved Corbevax and the Texas Children's team is further assisting with vaccine development capacity in Africa through a training program for scientists.

EnlitenAI Emerges as a Prominent Contender at the Digital Health Awards

Retrieved on: 
Friday, September 22, 2023

Fort Collins,CO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- EnlitenAI , an Innosphere Ventures graduate company, proudly announces its selection as a quarterfinalist in the prestigious Digital Health Awards presented by the Digital Health Hub Foundation.

Key Points: 
  • Fort Collins,CO, Sept. 22, 2023 (GLOBE NEWSWIRE) -- EnlitenAI , an Innosphere Ventures graduate company, proudly announces its selection as a quarterfinalist in the prestigious Digital Health Awards presented by the Digital Health Hub Foundation.
  • Out of an overwhelming 1,500 submissions, EnlitenAI has secured its spot due to its innovative focus on using AI to personalize seizure management.
  • This team has been instrumental not only in charting EnlitenAI’s functionality roadmap but also in designing groundbreaking clinical investigations."
  • Mark Goldstein, Chairman of Digital Health Hub Foundation, praised the high caliber of entrants this year, stating, "We are so impressed by the pioneering work in digital health happening on a global scale.

Motif Neurotech Conducts First-in-human Brain Stimulation With Millimeter-sized Implantable Device for Treatment-resistant Depression

Retrieved on: 
Monday, September 18, 2023

In intraoperative studies, the team showed that their miniature implants could safely and effectively stimulate the human brain without contacting the brain surface.

Key Points: 
  • In intraoperative studies, the team showed that their miniature implants could safely and effectively stimulate the human brain without contacting the brain surface.
  • They further showed their implants provided safe and effective brain stimulation in large animal studies lasting over 30 days.
  • Motif is developing a miniature brain pacemaker that is designed to precisely stimulate the brain to restore healthy circuit activity to treat mental health disorders.
  • “This tiny device, which cannot be seen once implanted, provides at-home stimulation that engages brain networks known to treat depression.